UC Berkeley-founded genome editing technology developer Caribou Biosciences has completed its first funding round in five years.

Caribou Biosciences, a US-based gene-editing technology spinout of University of California (UC) Berkeley, closed a $115m series C round on Wednesday co-led by Farallon Capital Management, PFM Health Sciences and Ridgeback Capital Investments.

AbbVie Ventures, the corporate venture capital unit of pharmaceutical firm AbbVie, and health system Heritage Medical Systems backed the round, as did cancer charity Leukemia and Lymphoma Society’s philanthropic venture arm Therapy Acceleration Program.

Adage Capital Partners, Avego Bioscience Capital, Avidity Partners, Invus, Janus Henderson Investors, LifeSci…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in